Checks prostate MRI screening in men with high genetic risk of prostate cancer
Studies prostate MRI screening in men with inherited gene changes or family history.
Plain-language title generated from the registry record
Registry title: Prostate Cancer Genetic Risk Evaluation and Screening Study
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Massachusetts General HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT05129605
- Record updated
- 10 November 2026
- Original description
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.Read full original descriptionShow less
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.
Inclusion: Individuals with a prostate aged 35 years or older; No known diagnosis of prostate cancer; Life expectancy >10 years; Meet cohort A, B, or C criteria; Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53); Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing; Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry.
Exclusion: Prior diagnosis or treatment of prostate cancer; Inability to undergo prostate MRI; Inability to receive MRI contrast agent.